Evidence map›Paper›PMID 35366888›Full record

ArticleJournal of nanobiotechnology2022

Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy.

Ting Zhao, Ce Liang, Yanrong Zhao, Xiangdong Xue, Zhao Ma, Jinlong Qi, Haitao Shen, Shaokun Yang, Jia Zhang, Qingzhong Jia and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Efficient ocular delivery of siRNAInternational journal of pharmaceutics: X · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Ting Zhao *Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Ce Liang *Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Yanrong Zhao *Department of Hematology, Hebei Children's Hospital, Hebei Medical University, Shijiazhuang, 050031, Hebei, China.
Xiangdong XueSchool of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai, 200240, China.
Zhao MaDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
Jinlong QiDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Haitao ShenLaboratory of Pathology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Shaokun YangKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Jia ZhangKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Qingzhong JiaKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Qing DuKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Deying CaoKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. deyingcao@hebmu.edu.cn.ORCID http://orcid.org/0000-0001-6221-2816
Bai XiangKey Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. baixiang@hebmu.edu.cn.
Hailin ZhangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. zhanghl@hebmu.edu.cn.
Xianrong QiSchool of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Hebei Medical University · CNPeking University · CNShandong University · CNShanghai Jiao Tong University · CN

Funding

Innovative Research Group Project of the National Natural Science Foundation of China H2020206474National Natural Science Foundation of China 81773666National Natural Science Foundation of China 81973251National Natural Science Foundation of China 82071533Natural Science Foundation of Hebei Province H2019206434Natural Science Foundation of Hebei Province H2019206445Postdoctoral Research Foundation of China 2015T80228
6 · The paper itself

Abstract

backgroundSmall interfering RNA (siRNA) is utilized as a potent agent for cancer therapy through regulating the expression of genes associated with tumors. While the widely application of siRNAs in cancer treatment is severely limited by their insufficient biological stability and its poor ability to penetrate cell membranes. Targeted delivery systems hold great promise to selectively deliver loaded drug to tumor site and reduce toxic side effect. However, the elevated tumor interstitial fluid pressure and efficient cytoplasmic release are still two significant obstacles to siRNA delivery. Co-delivery of chemotherapeutic drugs and siRNA represents a potential strategy which may achieve synergistic anticancer effect. Herein, we designed and synthesized a dual pH-responsive peptide (DPRP), which includes three units, a cell-penetrating domain (polyarginine), a polyanionic shielding domain (ehG)

resultsIn contrast to the results at the physiological pH (7.4), D-Lsi/DTX lead to the enhanced penetration into tumor spheroid, the facilitated cellular uptake, the promoted escape from endosomes/lysosomes, the improved distribution into cytoplasm, and the increased cellular apoptosis under mildly acidic condition (pH 6.5). Moreover, both in vitro and in vivo study indicated that D-Lsi/DTX had a therapeutic advantage over other control liposomes. We provided clear evidence that liposomal system co-delivering siPLK-1 and DTX could significantly downregulate expression of PLK-1 and inhibit tumor growth without detectable toxic side effect, compared with siPLK-1-loaded liposomes, DTX-loaded liposomes, and the combinatorial administration.

conclusionThese results demonstrate great potential of the combined chemo/gene therapy based on the multistage pH-responsive codelivery liposomal platform for synergistic tumor treatment.

Indexed as

Antineoplastic AgentsNeoplasmsDocetaxelHydrogen-Ion ConcentrationLiposomesRNA, Small InterferingAntineoplastic AgentsDocetaxelLiposomesRNA, Small InterferingCancer therapyCo-delivery systemDocetaxelLiposomepH-responsiveSmall interfering RNA

Identifiers

PMID35366888
PMCPMC8976966
OpenAlexW4226238797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.